US 11,739,144 B2
Heterodimeric antibodies that bind CD3 and CLDN6
Matthew S. Faber, Glendora, CA (US); Sung-Hyung Lee, San Gabriel, CA (US); Yoon Kyung Kim, Pomona, CA (US); Jing Qi, Arcadia, CA (US); Kendra N. Avery, Hawthorne, CA (US); Seung Y. Chu, Upland, CA (US); Alex Nisthal, Monrovia, CA (US); Matthew J. Bernett, Monrovia, CA (US); John R. Desjarlais, Pasadena, CA (US); and Chad Borchert, Nowthen, MN (US)
Assigned to Xencor, Inc., Pasadena, CA (US)
Filed by Xencor, Inc., Monrovia, CA (US)
Filed on Mar. 9, 2022, as Appl. No. 17/690,702.
Claims priority of provisional application 63/158,584, filed on Mar. 9, 2021.
Prior Publication US 2022/0289839 A1, Sep. 15, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 16/46 (2006.01); C12N 15/63 (2006.01)
CPC C07K 16/28 (2013.01) [A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/468 (2013.01); C12N 15/63 (2013.01)] 5 Claims
 
1. A composition comprising a bispecific antibody that binds human CD3 and human CLDN6 comprising:
a) a first monomer comprising the amino acid sequence set forth in SEQ ID NO: 567;
b) a second monomer comprising the amino acid sequence set forth in SEQ ID NO: 568; and
c) a third monomer comprising the amino acid sequence set forth in SEQ ID NO: 569.